Regeneron Pharma Q4 Results Top Estimates - Update

RTTNews | 306 days ago
Regeneron Pharma Q4 Results Top Estimates - Update

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.

Excluding items, adjusted earnings for the quarter $1.37 billion or $11.86 per share, compared to $1.45 billion or $12.56 per share in the year-ago quarter.

On average, 21 analysts polled by Thomson Reuters expected the company to report earnings of $10.87 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenue for the quarter edged up 1 percent to $3.43 billion from $3.41 billion in the same quarter last year. Excluding Ronapreve, revenue grew 14 percent. Analysts were looking for revenues of $3.29 billion for the quarter.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

read more
Regeneron Pharma Q2 Results Top Estimates - Update

Regeneron Pharma Q2 Results Top Estimates - Update

Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews | 125 days ago
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews | 159 days ago
Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Completes Acquiring Sanofi's Stake In Libtayo

Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews | 887 days ago
Win Streak May Continue For Indonesia Stock Market

Win Streak May Continue For Indonesia Stock Market

The Indonesia stock market has climbed higher in back-to-back sessions, gathering almost 280 points or 3 percent in that span. The Jakarta Composite Index now sits just above the 7,325-point plateau and it may add to its winnings on Thursday.
RTTNews | 5h 50min ago
Australian Market Modestly Higher

Australian Market Modestly Higher

The Australian market is trading modestly higher on Thursday, recouping the losses in the previous session, following the broadly positive cues from Wall Street overnight. The benchmark S&P/ASX 200 is moving up to just below the 8,500 level, with gains in gold miners, technology and financial stocks partially offset by weakness in iron miners and energy stocks.
RTTNews | 5h 53min ago
Hong Kong Shares May Bounce Higher On Thursday

Hong Kong Shares May Bounce Higher On Thursday

The Hong Kong stock market on Wednesday ended the three-day winning streak in which it had collected almost 380 points or 2 percent. The Hang Seng Index now sits just above the 19,740-point plateau although it may find renewed support on Thursday.
RTTNews | 6h 5min ago
Rebound Anticipated For China Stock Market

Rebound Anticipated For China Stock Market

The China stock market on Wednesday snapped the three-day winning streak in which it had advanced almost 85 points or 2.6. The Shanghai Composite now sits just beneath the 3,365-point plateau although it may bounce higher again on Thursday.
RTTNews | 6h 20min ago